Adam J. Gadzinski, MD, MS, on the Research Coming Out of SUO This Year

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting clinical instructor in the Department of Urology at the University of Washington, discussed what is most exciting about the research being presented this year at the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

Transcription:

I think a lot of the discussions have been around some of the new systemic treatments in prostate cancer and the genomic mutations in prostate cancer and how those are just now starting to guide our therapies for advanced prostate cancer. That's a very exciting place.

In the last 10 years, there's been numerous advances in men with metastatic prostate cancer. For decades, it was hormone suppression, whether that was achieved with shots or removing the testicles, and that was it. And now we're kind of an embarrassment of riches, and we keep getting more and now we're finding which specific ones work best for which specific patients with a subtype of cancer. So now we can accurately say we're getting to the personalized medicine that we've been talking a lot about for the last 20 years. We're finally getting there now.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Expert cardiologist
Related Content